Understanding Lokelma Prior Authorization with Medicare: What to Know in 2026

Written By

Dan Nandan

25+ Years Healthcare Outsourcing. CEO, Staffingly

▼

Dan Nandan is the CEO of Staffingly, Inc. With 25+ years in IT consulting and a decade leading healthcare BPO operations across India, Latin America, and Pakistan, his team now serves 800+ U.S. healthcare providers across medical, dental, pharmacy, and post-acute care verticals.

2026 Compliance Verified: HIPAA, SOC 2 Type II, ISO 27001, HITRUST-aligned workflows.

Featured in Computerworld →

Clinically Reviewed By

Bincy Kuriakose, MSN, RN

Clinical Content Reviewer. IL RN License #041.577729

▼

State of Illinois. Registered Professional Nurse

Bincy Shiiju Kuriakose is a U.S.-licensed Registered Nurse (MSN, RN), NCLEX-RN certified, with expertise in hospital nursing, telehealth, and nursing education. She reviews every publication for medical accuracy, YMYL compliance, and evidence-based clinical context.

Why Does Lokelma Require Prior Authorization Under Medicare?

• Lokelma is a potassium binder that lowers serum potassium by exchanging K+ for sodium and hydrogen in the GI tract
• FDA-approved in 2018 for hyperkalemia in adults (not for emergency use due to delayed onset)
• Retail cost approximately $1,027/month with no generic alternative available
• Medicare Part D places Lokelma on Tier 4 (non-preferred brand) or Tier 5 (specialty) in most formularies
• PA is Medicare’s mechanism to confirm: (1) documented hyperkalemia diagnosis, (2) medical necessity over lower-cost alternatives, (3) step therapy completion
• Key PA criteria across major payers: confirmed hyperkalemia with K+ >5.0 mEq/L, documented trial or contraindication to Kayexalate (SPS), supporting lab results and clinical records

In short, Medicare requires prior authorization on Lokelma because it is a higher-cost, non-preferred brand drug with no generic and a lower-cost legacy alternative (Kayexalate). The payer uses PA to confirm a documented hyperkalemia diagnosis with K+ >5.0 mEq/L, medical necessity over that alternative, and completion of step therapy before it will cover the prescription.

Step-by-Step Guide to Securing Lokelma Prior Authorization Under Medicare

The Lokelma PA process under Medicare Part D follows five practical stages, from pre-submission preparation through the post-decision steps. Each stage below reflects current payer documentation and timing requirements.

Step 1: Pre-Submission Preparation

• Check the patient's Part D formulary using AstraZeneca's formulary finder or the plan's online tool
• Gather: recent K+ lab values (must be >5.0 mEq/L), eGFR, comorbidity documentation (CKD stage, heart failure NYHA class, RAASi medication list)
• Identify ICD-10 code: E87.5 (Hyperkalemia)
• Document step therapy status: has patient tried/failed/contraindicated for Kayexalate?

Step 2: Complete the PA Request

• Online portal (fastest), fax, or phone submission depending on plan
• Include: letter of medical necessity, lab results showing elevated K+, treatment history, ICD-10 E87.5, prescriber NPI
• For Medicare Advantage with Part D: check plan-specific submission requirements

Step 3: Required Documentation Checklist

• Statement of medical necessity explaining why Lokelma over Kayexalate
• Lab results with potassium levels and dates
• Comorbidity documentation (CKD, HF, diabetes)
• Step therapy documentation (Kayexalate trial/failure/contraindication)
• Prescriber notes on clinical rationale

Step 4: Track and Follow Up

• Standard PA decisions: within 72 hours (per CMS rules)
• Expedited review: within 24 hours when patient health is at immediate risk
• Follow up daily if no response by day 3
• Document all communication with the PBM/payer

Step 5: After the Decision

• If approved: confirm pharmacy has coverage details, verify copay tier, inform patient about copay assistance options
• If denied: review the denial reason, gather additional documentation, file an appeal (coverage determination request)
• Appeal timelines: standard redetermination within 7 calendar days, expedited within 72 hours

ICD-10 and CPT Codes for Lokelma PA

• ICD-10: E87.5 (Hyperkalemia) — primary code for all Lokelma PA submissions
• Supporting ICD-10 codes: N18.1-N18.6 (CKD stages 1-5), I50.x (Heart failure), E11.x (Type 2 diabetes), N18.9 (CKD unspecified)
• CPT codes for related evaluation: 80051 (Electrolyte panel), 80053 (Comprehensive metabolic panel), 82565 (Creatinine)
• Accurate coding prevents delays and supports medical necessity documentation

How to Appeal a Lokelma Denial Under Medicare

• Common denial reasons: missing step therapy documentation, insufficient lab evidence, formulary exclusion, quantity limit exceeded
• Level 1 appeal (Redetermination): submit additional documentation to the Part D plan within 60 calendar days of denial. Include updated labs, detailed letter of medical necessity, peer-reviewed literature supporting Lokelma over alternatives
• Level 2 appeal (Reconsideration): if Level 1 is upheld, request independent review through the Independent Review Entity (IRE) within 60 days
• Level 3+ appeals: ALJ hearing, Medicare Appeals Council, Federal District Court
• Key stat: CMS OIG found that 81.7% of denied Medicare PA requests that were appealed were fully or partially overturned, indicating widespread initial over-denial
• Tip: for heart failure patients where Veltassa (sodium-free) may be clinically preferred, document why Lokelma’s rapid onset justifies the sodium risk if that is the clinical rationale
• Tip: request peer-to-peer review with the payer’s medical director if initial appeal is denied

The appeal narrative for Lokelma denials is typically stronger when it cites the FDA-approved indication language directly and includes the patient’s specific serum potassium values from the most recent lab draw. Generic appeal letters rarely succeed on Medicare Part D PA denials. A focused letter that ties the denial reason to the specific clinical facts of this patient, with lab dates, medication history, and CKD or heart failure staging, has a much higher overturn rate. Practices that handle a steady volume of these cases often lean on dedicated Medicare prior authorization services and step therapy override services to build the Kayexalate-failure narrative correctly the first time. For patients with recurrent hyperkalemia, include the frequency of elevated K+ events over the prior 6-12 months, as this demonstrates the need for chronic potassium management rather than episodic Kayexalate dosing.

When Medicare Part D plans deny Lokelma with “alternative available,” the alternative named is usually Kayexalate. The appeal strategy then centers on why Kayexalate is clinically inappropriate or insufficient for this patient. Documented black box warning concerns (colonic necrosis risk, particularly in post-surgical or bowel-compromised patients), hyperphosphatemia risk, or history of inadequate potassium control on Kayexalate all constitute valid clinical grounds. Pair this with the patient’s specific lab trajectory showing failed control on the alternative.

Lokelma Coverage by State: Georgia, Pennsylvania, and Illinois

Georgia

• Georgia Medicaid (managed care through Amerigroup, Peach State, CareSource): Lokelma requires PA with step therapy through Kayexalate
• Medicare Advantage penetration approximately 48% — nearly half of Georgia Medicare beneficiaries face MA-specific PA criteria
• Georgia has approximately 1.1 million adults with CKD (CDC data), driving significant hyperkalemia management demand

Pennsylvania

• Highmark pharmacy policy J-0474 covers Lokelma and Veltassa under a combined potassium binder policy: requires K+ >5.0 mEq/L and documented Kayexalate trial/failure/contraindication
• Pennsylvania Medicaid (HealthChoices MCOs): PA required, formulary varies by managed care plan
• Major health systems (UPMC, Penn Medicine) process high volumes of specialty drug PAs

Illinois

• Illinois Medicaid MCOs (IlliniCare, Meridian, Molina, BCBS of IL): Lokelma requires PA with Kayexalate step therapy
• HB 3308 (effective 2024) requires Medicaid MCOs to respond to urgent PA requests within 24 hours — applicable when K+ is critically elevated
• Cook County and Chicago metro have among the highest CKD prevalence rates in the Midwest

Six Common Lokelma PA Mistakes and How to Avoid Them

Lokelma denials cluster around the same six errors. Fixing these raises first-pass approval rates noticeably.

1. Submitting without a current K+ lab value. Most Part D plans want a potassium reading above 5.0 mEq/L drawn within the last 30 days. A lab from three months ago gets flagged. If the patient is not currently hyperkalemic, the PA will be denied. Redraw before submission.

2. Skipping the Kayexalate step therapy documentation. Plans expect a documented trial, contraindication, or intolerance to Kayexalate first. “Patient has CKD, start Lokelma” is not enough. Document the specific Kayexalate history: dose, duration, outcome, or the specific contraindication (bowel ischemia, colonic necrosis risk, post-surgical bowel status).

3. Missing the heart failure rationale for sodium content. Lokelma contains 400mg sodium per 5g dose. For heart failure patients, payers challenge whether Veltassa (sodium-free) would be more appropriate. The PA must explicitly address why Lokelma’s rapid onset outweighs the sodium load for this specific patient.

4. Using E87.5 as the only ICD-10 code. Pair hyperkalemia (E87.5) with the underlying etiology: N18.x for CKD stage, I50.x for heart failure, E11.x for T2DM with CKD. The full picture supports the medical necessity argument.

5. Not using 24-hour expedited review. When the patient’s K+ is critically elevated (above 6.0 mEq/L), the PA qualifies for 24-hour expedited review. Practices that submit these as standard requests force the patient through 72-hour standard timing when urgent timing is available.

6. Missing the 60-day appeal window. Medicare Part D redetermination must be filed within 60 calendar days of denial. Practices that miss this window lose the fastest appeal path and must start over with a new PA submission, extending the patient’s therapy gap.

What most Lokelma PA guides will not admit: The Kayexalate step therapy requirement is often clinically absurd but still administratively unavoidable. Kayexalate has a black box warning for colonic necrosis, and most nephrologists have not prescribed it routinely in years. Yet Part D plans keep it as the required step because it is cheap and its black box warning does not technically disqualify it as a tried-and-failed agent. Rather than fight the requirement, build the appeal around “documented contraindication” language from day one. Pre-write a Kayexalate contraindication letter template for every new Lokelma patient that cites colonic ischemia risk, post-surgical bowel status, concurrent opioid use, or hyperosmolar risk. Attach it to the first PA, not the appeal. You will skip one round of denial and save two weeks of therapy gap. The practices that figured this out are running Lokelma first-pass approval rates above 80%. The ones still submitting naked PAs and fighting on appeal are stuck at 45-50%.

Lokelma vs Veltassa: Which Potassium Binder Gets Approved Faster?

• Both require PA under Medicare Part D with similar step therapy requirements (Kayexalate trial first)
• Lokelma advantage: faster onset (~1 hour vs hours-to-days for Veltassa), making it the preferred choice for acute-on-chronic hyperkalemia
• Veltassa advantage: sodium-free formulation, making it preferred for heart failure patients with fluid overload risk
• PA documentation tip: if prescribing Lokelma for a heart failure patient, explicitly document why rapid onset outweighs sodium risk — this prevents payer pushback
• Neither has a generic alternative. Both carry similar retail costs ($800-$1,500/month range). The lack of generic competition means PA requirements are unlikely to loosen in the near term, and practices should plan for continued PA workload for both agents
• Some Part D plans prefer one over the other on their formulary — always check the specific plan’s preferred drug list before prescribing to avoid a formulary-driven denial

Managing Lokelma PA for CKD and Heart Failure Patients

CKD and heart failure patients present the most frequent Lokelma PA scenarios because hyperkalemia recurs in both populations, particularly when patients are on RAAS inhibitors (ACE inhibitors, ARBs, or spironolactone) that are guideline-directed therapies for their underlying condition. The clinical dilemma is real: the medications that protect these patients’ hearts and kidneys also raise their potassium levels, creating a cycle where the treatment for one condition triggers the need for treatment of another.

For nephrology and cardiology practices managing 20 or more patients on RAAS inhibitors with recurrent hyperkalemia, Lokelma PA management becomes a recurring administrative task that consumes significant staff hours. Each patient needs an initial PA submission with step therapy documentation, then periodic reauthorization every 6-12 months with updated K+ values and current comorbidity staging to keep coverage in place.

Prior authorization requirements continue to increase across all payer types. The AMA’s 2024 Prior Authorization Physician Survey found that physicians complete an average of 43 PA requests per week, with each request consuming significant staff time. For practices handling specialty medications, imaging studies, or surgical procedures, the PA workload can consume 12 or more staff hours per week. That is time pulled directly from patient care activities and revenue-generating tasks.

The financial impact goes beyond staff time. Delayed authorizations mean delayed treatment, which affects patient satisfaction scores and can trigger downstream complications that cost more to treat. Practices report that PA-related delays contribute to appointment cancellations, no-shows, and patient attrition to competitors who can get approvals faster. When a patient waits two weeks for an authorization that should have taken three days, the practice relationship suffers regardless of whether the delay was the payer’s fault or the staff’s.

The denial rate for prior authorizations adds another layer of cost. When a PA request is denied, staff must research the reason, gather additional documentation, schedule peer-to-peer reviews with payer medical directors, and file formal appeals. Each denied PA represents 3-5 additional hours of staff work beyond the initial submission. Multiply that across dozens of denials per month and the cost becomes unsustainable for many practices.

Outsourcing PA to a dedicated team with payer-specific expertise addresses both the time and quality problems. Staffingly’s PA specialists handle the full authorization lifecycle from initial submission through peer-to-peer reviews and formal appeals, and pair it with specialty drug insurance clearance so coverage and step-therapy details are confirmed before the script is sent. Working across 50+ EHR platforms and serving 800+ providers, Staffingly goes live within 48-72 hours at $399/week (volume discounts to $299/week) with a 99.2% clean claim rate. The 15-Day Risk-Free Pilot lets practices test the service with zero upfront cost and no long-term contract required.

Frequently Asked Questions